Association between Paraoxonase-1 Activity and Insulin Resistance among Iraqi Prediabetic and Newly Diagnosed Type 2 Diabetic Patients
DOI:
https://doi.org/10.47419/bjbabs.v7i3.426Keywords:
Paraoxonase-1, insulin resistance, prediabetes, newly diagnosed type 2 diabetes mellitus, Iraqi populationAbstract
Objective: This research study aimed to investigate the role of paraoxonase-1 (PON1) in insulin resistance and beta-cell dysfunction in individuals with prediabetes and newly diagnosed type 2 diabetes mellitus (T2DM) in an Iraqi population sample.
Methods: This study included 150 patients in total: 60 prediabetics, 27 diabetics, and 63 controls. The lipid profile, clinical features, and other biochemical data of the participants were examined. To investigate the connections between various characteristics in the prediabetic and recently diagnosed T2DM groups, Pearson correlation analysis was used. The potential of PON as a differentiating marker between various combinations of the research groups was assessed using receiver operating characteristic (ROC) analysis.
Results: The distribution of sexes in the control, diabetes, and prediabetic groups did not differ significantly (p = 0.1728). The group with diabetes had the highest mean age, and there was a significant difference in mean age between the groups (p < 0.001). Weight, body mass index, and waist circumference all showed significant variations (p < 0.001), with the greatest mean value being displayed by the diabetic group. Insulin levels, PON levels, and the homeostatic model evaluation of insulin resistance (HOMA-IR) all showed significant variations between the groups (p < 0.001). Both the prediabetic and newly diagnosed T2DM groups showed significant negative associations between PON and insulin and between PON and HOMA-IR. PON had strong discriminatory ability in differentiating between diabetics and controls, prediabetics and controls, and diabetics and prediabetics, according to the ROC analysis.
Conclusion: According to the results of this investigation, PON may contribute to insulin resistance and beta-cell dysfunction in the Iraqi population with prediabetes and newly diagnosed type 2 diabetes. Significant correlations were found between PON levels and insulin and HOMA-IR, and it showed promise as a marker of distinction between various study group combinations. To clarify the underlying mechanisms and clinical consequences of PON in the pathophysiology and treatment of prediabetes and type 2 diabetes, more investigation is necessary.
Downloads
References
[1] Adiga, U.; Nandit, B.; Desy, T.M. Association of paraoxonase 1 activity and insulin resistance models in type 2 diabetes mellitus: cross-sectional study. J. Chin. Med. Assoc. 2022; 85: 77–80. https://doi.org/10.1097/JCMA.0000000000000665
[2] Andreadi, A.; Alfonso, B.; Nicola, D.D.; Marco, M.; Renato, L.; David, D.-M.; Davide, L. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: a target for new therapies against cardiovascular diseases. Curr. Opin. Pharmacol. 2022; 62: 85–96. https://doi.org/10.1016/j.coph.2021.11.010
[3] Awad, N.A.; Zeena, A.A.; Mohammed, A.M.A.; Shaimaa, S.M. Correlation study of metformin drug with vit. B12 and folic acid in women suffer of type 2 diabetic disease. J. Pharm. Negat. Results. 2022; 13. https://doi.org/10.47750/pnr.2022.13.03.049
[4] Bednarz-Misa, I.; Izabela, B.; Marzena, Z.; Błażej, M.; Bogdan, Z.; Sylwia, P.; Mariusz, F.; Jerzy, W.; Andrzej, G.; Małgorzata, K.-K. Paraoxonase 1 decline and lipid peroxidation rise reflect a degree of brain atrophy and vascular impairment in dementia. Adv. Clin. Exp.Med. 2020; 29:71–78. https://doi.org/10.17219/acem/111377
[5] Branch, M.; Charles, G.; Alain, B.; Joseph, Y. Incremental risk of cardiovascular disease and/or chronic kidney disease for future ASCVD and mortality in patients with type 2 diabetes mellitus: ACCORD trial. J. Diabetes Complicat. 2019; 33: 468–72. https://doi.org/10.1016/j.jdiacomp.2019.04.004
[6] Coculescu, B.I.; Tudor, H.; Ioan, S.T.; Gheorghe, M. PON-1, possible biomarker for diagnosis but also for risk in diastolic dysfunction with preserved ejection fraction. Rev Chim (Bucharest). 2019; 70: 1210–4. https://doi.org/10.37358/RC.19.4.7093
[7] Cohrs, C.M.; Julia, K.P.; Denise, M.D.; Stephen, J.E.; Nicole, K.;Chunguang, C.; Robert, B.; Eyke, S.; Florian, E.; Marius, D. Dysfunction of persisting β cells is a key feature of early type 2 diabetes pathogenesis. Cell Rep. 2020; 31. https://doi.org/10.1016/j.celrep.2020.03.033
[8] Griffiths, K.; Agnieszka, P.; Mohammed, A.; Anne, M.; Alexander, P.M.; Jane, M.; James, G.; Gareth, J.M. Type 2 diabetes in young females results in increased serum amyloid A and changes to features of high density lipoproteins in both HDL and HDL. J. Diabetes Res. 2017; 1314864. https://doi.org/10.1155/2017/1314864
[9] Grzegorzewska, A.E.; Paulina, A.; Ewa, I.-S.; Kamila, O.; Leszek, N.; Wojciech, M.; Adrianna, M.; Wojciech, W.; Czesław, Ż.; Paweł, P.J. Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients. Sci. Rep. 2021; 11: 6773. https://doi.org/10.1038/s41598-021-86231-0
[10] Hasselwander, O.’; Jane, M.; McMaster, D.; Fogarty, D.G.; Nicholls, D.P.; Maxwell, A.P.; Young, I.S. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis. Atherosclerosis. 1999; 143: 125–33. https://doi.org/10.1016/S0021-9150(98)00286-X
[11] Huang, Y.; Zhang, H.F.; Pan, X.; Yang, Z.; Yu, J. Novel biomarkers and risk factors associated with cardiometabolic dysfunction in heart failure (Frontiers Media SA). 2023. https://doi.org/10.3389/978-2-83251-904-2
[12] Koren-Gluzer, M.; Michael, A.; Tony, H. Paraoxonase1 (PON1) reduces insulin resistance in mice fed a highfat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway. Atherosclerosis. 2013; 229: 71–78. https://doi.org/10.1016/j.atherosclerosis. 2013.03.028
[13] Li, M.; Xiaowei, C.; Ying, W.; Sarra, S.; Wenwei, X.; Hanmei, X. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct. Target. Ther. 2022; 7: 216. https://doi.org/10.1038/s41392-022-01073-0
[14] Meneses, M.J.; Regina, S.; Inês, S.-L.; Maria, P.M. Paraoxonase-1 as a regulator of glucose and lipid homeostasis: impact on the onset and progression of metabolic disorders. Int. J. Mol. Sci. 2019; 4049. https://doi.org/10.3390/ijms20164049
[15] Mirahmadizadeh, A.; Mohammad, F.; Ali, M.M.; Shahryar, Z.; Soheil, H.; Alireza, H. The prevalence of undiagnosed type 2 diabetes and prediabetes in Eastern Mediterranean region (EMRO): a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2020; 160: 107931. https://doi.org/10.1016/j.diabres.2019.107931
[16] Motta, B.P.; Camila, G.P.; Ingrid, D.F.;, Felipe, N.C.; Juliana, O.O.; Rachel, T.A.M.; Patrícia, B.d.S.; Marlus, C.; Iguatemy, L.B.; Amanda, M.B. Combined effects of lycopene and metformin on decreasing oxidative stress by triggering endogenous antioxidant defenses in diet-induced obese mice. Molecules. 2022; 27: 8503. https://doi.org/10.3390/ molecules27238503
[17] Öztaş, B.; Fatma, C.E.; Hale, M.K. 2022. Serum paraoxonase 1 as a biomarker: features and applications in type 2 diabetes mellitus. in, Biomarkers in Diabetes (Springer). https://doi.org/10.1007/978-3-030-81303-1_22-1
[18] Polidori, N.; Francesca, M.; Francesco, C.; Angelika, M.; Cosimo, G. Early insulin resistance, type 2 diabetes, and treatment options in childhood. Horm. Res. Paediatr. 2022; 95: 149–66. https://doi.org/10.1159/000521515
[19] Ravi, R.; Nareshkumar, R.N.; Bharathidevi, S.R. Effect of advanced glycation end product on paraoxonase 2 expression: its impact on endoplasmic reticulum stress and inflammation in HUVECs. Life Sci. 2020; 246: 117397. https://doi.org/10.1016/j.lfs.2020.117397
[20] Rosta, V.; Alessandro, T.; Angelina, P.; Giovanni, Z.; Juana, M.S.; Cristina, B.; Gloria, B.; Tiziana, B.; Carlo, C. Sex difference impacts on the relationship between paraoxonase-1
(PON1) and type 2 diabetes. Antioxidants. 2020; 9: 683. https://doi.org/10.3390/antiox9080683
[21] Sarıkaya, U.; Sedat, M.; Şahabettin, S; Alime, S.; Metin, D.; Ayşe, Z.G.;Tuğçe, Y. Could the PON1 phenotype play a key role in insulin resistance? Int. J. Diabetes Dev. Ctries. 2022; 1–6. https://doi.org/10.1007/s13410-022-01096-x
[22] Wamique, M.; Wahid, A.; Himanshu, D.R.; Preeti, V.; Mohd, W. A case control study on HDL associated PON1 enzyme level in Northern Indian type 2 diabetes mellitus patients. Diabetes Metab. Syndr.: Clin. Res. Rev. 2018; 12: 843–47. https://doi.org/10.1016/j.dsx.2018.03.005
[23] Zhang, J.; Xiangling, Y.; Lili, W.; Huiliu, T.; Junxiong, C.; Weiqian, L.; Kawo, C.; Yixi, S.; Lu, Z.; Suhua, H. Improved diagnostic value by combining plasma PON1 level with tumor biomarkers in colorectal cancer patients. J. Cancer. 2020;11: 6491. https://doi.org/10.7150/jca.45204
Additional Files
Published
Issue
Section
Categories
License
Copyright (c) 2026 Osamah Adnan, Mohammed Imran Hamza
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain all proprietary rights, including copyright, such as patent and trademark rights and rights to any process or procedure described in the article.
